MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Inicio・Lista de Acciones・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Abierto

SectorSalud

4.09 -0.24

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

4.05

Máximo

4.1

Métricas clave
By Trading Economics
Ingresos	9.6M -162M
Ventas	-14M 5.2M
Margen de beneficio	-3,135.324
Empleados	800
EBITDA	6.4M -141M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+88.56% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-222M 2.2B
Apertura anterior	4.33
Cierre anterior	4.09

Noticias sobre sentimiento de mercado

By Acuity

50%

157 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

4.15 / 4.75 Soporte y Resistencia

Recursion Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

31 dic 2025, 22:20 UTC

Principales Movimientos del Mercado

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31 dic 2025, 17:31 UTC

Principales Movimientos del Mercado

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31 dic 2025, 16:30 UTC

Principales Movimientos del Mercado

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31 dic 2025, 15:19 UTC

Principales Movimientos del Mercado

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31 dic 2025, 15:17 UTC

Principales Movimientos del Mercado

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31 dic 2025, 14:37 UTC

Principales Movimientos del Mercado

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

31 dic 2025, 21:13 UTC

Adquisiciones, fusiones, absorciones

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31 dic 2025, 20:40 UTC

Charlas de Mercado

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31 dic 2025, 20:22 UTC

Charlas de Mercado

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31 dic 2025, 19:50 UTC

Charlas de Mercado

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31 dic 2025, 19:31 UTC

Charlas de Mercado

Precious Metals Cap Off Record Runs -- Market Talk

31 dic 2025, 18:50 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

31 dic 2025, 18:50 UTC

Charlas de Mercado

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31 dic 2025, 17:17 UTC

Charlas de Mercado

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31 dic 2025, 17:16 UTC

Principales Movimientos del Mercado

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31 dic 2025, 17:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

31 dic 2025, 17:00 UTC

Adquisiciones, fusiones, absorciones

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31 dic 2025, 15:57 UTC

Adquisiciones, fusiones, absorciones

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31 dic 2025, 15:54 UTC

Charlas de Mercado

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31 dic 2025, 15:02 UTC

Principales Movimientos del Mercado

Nike Shares Rise After CEO Hill Buys $1M of Shares

31 dic 2025, 14:40 UTC

Adquisiciones, fusiones, absorciones

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31 dic 2025, 14:20 UTC

Charlas de Mercado

Crude Futures On Track to End the Year With Losses -- Market Talk

31 dic 2025, 13:46 UTC

Charlas de Mercado

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31 dic 2025, 13:01 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31 dic 2025, 11:10 UTC

Charlas de Mercado

Copper Remains in Touching Distance of Record Highs -- Market Talk

31 dic 2025, 10:46 UTC

Charlas de Mercado

Euro on Track For Strong Annual Performance -- Market Talk

31 dic 2025, 10:25 UTC

Charlas de Mercado

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31 dic 2025, 10:23 UTC

Charlas de Mercado

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31 dic 2025, 09:33 UTC

Charlas de Mercado

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Comparación entre iguales

Cambio de precio

Recursion Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

88.56% repunte

Estimación a 12 meses

Media 7.75 USD 88.56%

Máximo 11 USD

Mínimo 5 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Recursion Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

Comprar

Mantener

Vender

De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para Recursion Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

4.15 / 4.75Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentimiento

By Acuity

157 / 374 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.